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The classic features of Down syndrome (DS) may not initially be apparent in extremely premature 
newborns. Rarely, DS will present in association 
with a haematologic entity referred to as transient 
myeloproliferative disorder (TMD), also known as 
transient leukaemia (TL). TMD can be self-limiting 
with an estimated incidence of 10% in patients with 
DS. However, in 20–30% of cases it may transform 
to true leukaemia.1,2 We report an extremely 
premature neonate with mosaic Down syndrome 
(MDS) who appeared phenotypically normal and 
presented with multisystem dysfunction, TMD, and 
subsequently developed acute myeloid leukaemia 
(AML).  
Case Report
A male neonate was born at 26 weeks of 
postmenstrual age to non-consanguineous 
parents. The mother was a 31-year-old known 
asthmatic G7P6A1. Her intrapartum course was 
complicated by placenta abruptio; hence, the baby 
was born by an emergency Caesarean section and 
the mother lost a litre of blood during delivery. In 
view of the neonate’s poor general condition and 
marked pallor at birth, immediate resuscitation and 
ventilatory support were rendered. The right hand 
was noticeably blanched and had turned cyanotic. 
The radial and ulnar pulses were not palpable. 
There were no apparent dysmorphic features. The 
growth parameters were adequate for gestational 
age; the baby’s birth weight was 1,020 gr, body 
length was 34 cm, and head circumference 24 
cm. In the first 24 to 48 hours of life, the baby had 
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اضطراب الَتكاثري الِنْقِيّي املؤقت ومتالزمة داون
 هل مثة رابط؟
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امللخ�ص: ُعرَض علينا وليد ذكر خديج للغاية مصاب باضطراب غري عادي يف أجهزة اجلسم املتعددة خالل اليومني األوليني من حياته. وقد بّينت 
األحداث السريرية والفحوصات اضطراب التكاثري النقيي املؤقت. وقد كان ذلك االضطراب السبب  الرئيسي للتنميط النووي هلذا الرضيع اخلديج بدون 
وجود وصمات ممّيزة ملتالزمة داون. معرفة وجود اضطراب التكاثري النقيي املؤقت لدى وليد تستوجب التنميط النووي حبثا عن التثلث الصبغي 21، 
والرتّصد الدقيق للحالة وذلك إلمكانية تطوره إىل ابيضاض الدم.
مفتاح الكلمات: ا�صطراب التكاثري النقيّي املوؤقت، متالزمة داون الف�صيف�صائية، ابي�صا�ض الدم النقوي احلاد، تقرير حالة، ُعمان. 
abstract: An extremely premature male neonate presented with an unusual multisystem dysfunction within the 
first 24 to 48 hours of life. The unfolding of clinical events and investigations revealed a transient myeloproliferative 
disorder (TMD). TMD was the main indication for karyotyping of this premature infant without clinical symptoms 
of Down syndrome. The awareness of TMD in a newborn warrants karyotype analysis to look for trisomy 21 and a 
close surveillance because of its potential progression to true leukaemia.
Keywords: Extreme premature; Transient myeloproliferative disorder; Down syndrome; GATA1; Acute myelogenous 
leukemia (AML); Case report; Oman.
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severe respiratory distress syndrome (RDS) that 
was treated with a surfactant. The major concern 
then was the apparent vascular compromise of the 
right hand, but there was no identifiable reason 
for the condition. Heparin was administered for 
a few hours and discontinued when the neonate’s 
activated partial thromboplastin time (APPT) 
rose to 180 seconds. The right hand became pink 
on the 4th day and his pulses returned to normal 
by the 12th day. The possibility of feto-maternal 
haemorrhage as the cause of the neonate’s marked 
anaemia (haemoglobin 9.3 gr/dl) was unproven.
The skin was thick and marked by scattered 
vesiculopustular lesions in the perianal area. 
Evaluation of and treatment for infection was 
indicated by the probability of a staphylococcal 
sepsis. Weekly blood cultures in the first 6 weeks of 
life and a culture of the skin lesions for bacterial and 
viral infections such as cytomegalovirus (CMV), 
herpes, parvovirus, mumps, and enteroviruses were 
negative. The skin appeared normal after 2 to 3 
weeks.
The initial complete blood count (CBC) from 
the cord sample showed pancytopenia. The trend 
of the serial CBC during the first two weeks of 
life showed leukocytosis of 30–59 x 109/L and an 
absolute neutrophil count (ANC) of 10–37 x 109/L. 
His platelet count decreased from day 20. Blast cells 
were seen on the peripheral smear on the first day of 
life [Table 1]. The leukaemia immunophenotyping 
done on the third day of life revealed that the blasts 
were CD 13, 33, 34, 117 and HLA-DR positive, 
consistent with acute myeloid leukaemia (AML), 
and were negative for lymphoid markers [Figure 1]. 
These immature blast cells were considered unique 
to prematurity or possibly secondary to trisomy 21. 
The diagnosis of TMD was based on the persistence 
of blast cells on serial peripheral smears beyond one 
week of life [Figure 1]. Earlier physical examinations 
had shown no clinical features consistent with DS. 
However at about 33 weeks of gestation, a few 
features, such as epicanthal folds and the low nasal 
bridge of DS, were noticeable. The cytogenetic 
analysis revealed MDS 47,XY,+21/46, XY.
On the second day of life, the baby developed 
intractable segmental myoclonus characterised 
as spontaneous and stimulus-sensitive, and 
involving the palate, and upper and lower limbs. 
The seizures were controlled completely on the 
third week with triple anticonvulsants, namely 
phenobarbital, phenytoin, and levetiracetam. The 
electroencephalogram (EEG) showed a burst-
suppression-like pattern with spike-and-wave 
discharges. There were no structural abnormalities 
or thrombosis identified on a magnetic resonance 
imaging (MRI) scan of the brain. 
The comorbidities that arose during the 
baby’s adverse clinical course were the following: 
bronchopulmonary dysplasia (BPD); Stage 2 Zone 
II retinopathy of prematurity (ROP) that  required 
laser therapy; cholestasis, and osteopenia of 
prematurity (OOP).  














RBC 1012/L 1.72 2.32 4.38 4.29 5.35 4.05
Haemoglobin 
gm/dL 
6 9.3 13.7 11.6 12.8 10.2
Haematocrit 
L/L 
0.17 0.27 0.39 0.34 0.40 0.31 
MCV fL 101 116 88 80.3 74.9 75.7 
MCH pg 35.1 40.5 31.3 27.0 23.9 25.1 
MCHC g/L 34.9 34.8 35.5 33.7 31.9 33.2 
RDW % 27.3 20.2 20.7 24.2 22.5 21.9 
NRBC 109/L 0.9 4.6 0 0.4 0.4 0
Platelet count 
109/L 
21 328 309 119 301 67 
WBC 109/L 8.6 44.9 56.7 59.6 36.9 11.4 
Neutrophils 
109/L 
2.3 5.2 22.8 43.9 27.1 5.2 
Lymphocytes 
109/L 
5.4 21.2 21.7 12 8.1 5.2 
Monocytes 
109/L 
0.9 17.2 11.9 3.6 1.5 0.9 
Eosinophils 
109/L 
0.1 1.2 0.2 0.2 0.1 0
Basophils 
109/L 
0 0.1 0.1 1.1 0 0
Retics % 4.2 5.8 2.3 0.8 1.1 0.8
Retics 
absolute 






+ + + + + +
RBC = red blood cells; MCV = mean corpuscular volume; MCH = mean 
corpuscular haemoglobin; MCHC = mean corpuscular haemoglobin 
concentration; RDW = red blood cell distribution width; NRBC = nucleated 
red blood cells; WBC = white blood cells.
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He was discharged at 85 days of life with growth 
parameters below the 3rd centile; he weighed 2,160 
gr, and was 42 cm in length, with an HC of 29 cm. 
The baby’s subsequent follow-up would prove to 
be critically important given his history of TMD. 
The monitoring protocol used was a CBC every 3 
months. The haematological problem resolved at 6 
months of age. There were difficulties encountered 
in obtaining an adequate specimen from serial 
bone marrow aspirates (BMA) at 6 months and 
16 months. The findings each time showed no 
leukaemic markers. However, in the presence of 
progressive hepatosplenomegaly (HSM) from 
16 months of age, a repeat BMA at 17 months of 
age confirmed the finding of AML [Figure 2]. His 
immunophenotype by flowcytometry showed a 
biphenotypic leukaemia with positive lymphoid 
and myeloid markers, with a predominance of the 
latter. He was treated using the 2007 treatment 
protocol for AML-DS, which consisted of a total of 
four courses of chemotherapy, with two induction 
courses followed by two consolidations. The 
chemotherapy in the induction course included 
cytarabine, idarubicin, etoposide, and intrathecal 
cytarabine. In the consolidation phase, the 
chemotherapy included high dose cytarabine and 
mitoxanthrone. Presently, the baby is 3 years old 
and has been in remission since 2 years of age.
Discussion
DS is the most common recognised chromosomal 
abnormality, occurring in 1: 1000 live births. Full 
trisomy 21 presents in 94% of patients, MDS in 
2.4%, and translocations in 3.3%.3 In MDS, there 
are two populations of cell lines—a normal cell 
line with 46 chromosomes and a second line with 
trisomy 21. In patients with MDS, clinical features 
vary from normal to subtle to full expression of 
DS depending on the level and distribution of the 
trisomic cells within the tissues.4   Our patient was 
a confirmed case of MDS who initially presented 
without clinical features of DS. 
All cytogenetic types of DS are predisposed 
to develop leukaemia. Approximately 10% of 
people with DS present with TMD and, after 
initial resolution, a significant proportion 
(20–30%) may subsequently develop any of the 
following: acute myelogenous leukaemia (AML), 
acute lymphoblastic leukaemia (ALL), or acute 
megakaryocytic leukaemia (AMKL). More 
recent studies have implicated the mutagenesis of 
haematopoietic transcription of factor gene GATA 
1 as an initiating agent in DS leukaemogenesis.5 
The GATA 1 gene, located on the X chromosome, 
encodes a zinc-finger transcription factor that is 
essential for normal erythroid and megakaryocytes 
differentiation. Somatic mutations in exon 2 of 
GATA1 have been detected exclusively in trisomy 
 
Figure 1: Peripheral smears in the first 2 weeks of life, with blasts cells indicated by red arrows.
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21-associated TL as well as non-DS related AMKL. 
There are three cooperating events in 
pathogenetic steps in AML-DS: trisomy 21, the 
GATA1 mutation (GATA1s), and an undefined 
genetic alteration. However, it remains unclear 
which factors in the chromosome 21 cooperate 
with the oncogenic GATA1s and which factors 
drive this transition from preleukaemia to AML-
DS. The blast cell sensitivity to chemotherapy 
in AML-DS has been linked to the gene-dosage 
effect of chromosome 21 localised genes that leads 
to an increased level in the expression of 
cystathionine beta-synthase, contributing to 
cytarabine sensitivity. The generation of GATA1s 
results in interactions and modulation of the 
expression of different genes, such as the cytidine 
deaminase gene (CDA) localised to chromosome 
1. CDA is involved in the irreversible hydrolytic 
deamination of ara-C (cytarabine) to the inactive 
ara-U (uracil). The expression of anti-apoptotic 
proteins such as BCL2 (whose gene, BCL2, 
is localised to chromosome 18), and HSP70 
(whose gene, HSP70, is localised to chromosome 
5) is lower in DS AML blasts, suggesting that 
DS megakaryoblasts are more susceptible to 
chemotherapy-induced apoptosis. Overexpression 
of CBS has been correlated with in vitro generation 
of ara-CTP, the active intracellular ara-C metabolite, 
and subsequent increased ara-C sensitivity in DS 
AML blast cells.6
Our patient was diagnosed with TMD on the 
basis of the 6-month persistence of blast cells, and 
its resolution was based on serial BMA findings 
negating the presence of leukaemia. However, the 
presence of hepatosplenomegaly at 16 months 
indicated that the TMD was not transient and 
had progressed to AML. The difficult in aspirating 
specimens in the earlier BMAs may have been due 
to hypercellularity and myelofibrosis, an antecedent 
myelodysplastic phase. Extreme prematurity, 
significant early leukocytosis, and the reappearance 
of blast cells after an apparent resolution were 
considered risk factors for the progression to true 
leukaemia.
The appearance of the neonate’s right hand 
at birth gave rise to major concerns about an 
acute vascular compromise or a thromboembolic 
episode. Neonates are particularly susceptible 
to thromboembolic diseases because of the 
relative immaturity of the homeostatic system 
and the potential presence of serious underlying 
disease.7 Investigations to identify its cause ruled 
out congenital and acquired thrombophilia, and 
cyanotic heart disease. The right hand may have 
been entrapped during delivery, leading to an acute 
arterial vasospasm. The surveillance for the long 
term effects of this event showed no disparity in 
growth of the upper limbs. 
There are many possible causes of 
vesiculopustular eruptions in babies, but the 
commonest is infection. Its appearance in our 
patient coincided with leukocytosis, and persistence 
of blast cells. Whether these lesions represented 
the leukaemic cutis associated with TMD was 
 
Figure 2: Serial bone marrow aspirates (BMA) images with blasts cells at 17 (A), 18 (B), 19 (C), and 22 (D) months of age. 
Please note the absence of blast cells at 22 months when the patient was in remission (E & F). 
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something that was not investigated.7 There are 
reports in the literature of neonates presenting with 
TMD and cutaneous lesions without morphologic 
features of DS that were proven to have MDS.8–10 
In hindsight, both the unusual slow-healing skin 
lesions and TMD should have served as clues 
to the identification of DS in the baby. The early 
development of intractable seizures was considered 
hypoxia-induced due to the neonate’s severe 
anaemia at birth. 
Conclusion
Neonates, especially extremely premature babies, 
with an easily recognised syndrome like DS may not 
present initially with significant physical features; 
however, DS may present as its rarest associated 
clinical problem, TMD. 
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